Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE

Executive Summary

Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.

You may also be interested in...



Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price

But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity

The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure on new longer acting insulins to demonstrate superior cost-efficacy compared to standard of care Lantus to gain preferential formulary placement. This has become significantly more difficult with the US launch of Lilly's biosimilar, Basaglar.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel